Otsuka Presents VISIONARY Two-Year eGFR Results Demonstrating Stabilisation of Kidney Function with sibeprenlimab in IgAN
Otsuka Presents VISIONARY Two-Year eGFR Results Demonstrating Stabilisation of Kidney Function with sibeprenlimab in IgAN
Otsuka Presents VISIONARY Two-Year eGFR Results Demonstrating Stabilisation of Kidney Function with sibeprenlimab in IgAN
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)